Our primary focus is on the inhibition of fatty acid synthase (FASN), a pivotal controller of lipid production. FASN activity is elevated in specific ailments such as nonalcoholic steatohepatitis (NASH) and certain types of tumors. We are of the opinion that targeting FASN could lead to clinical advantages. Our leading drug candidate, TVB-2640, is an oral medication with high potency, selectivity, and reversibility, making it the first of its kind in inhibiting FASN and is currently in clinical development. Preliminary Phase 1 trials have demonstrated that TVB-2640 hinders the creation of new fats in cancer patients and diminishes the synthesis of liver fats in individuals exhibiting traits of metabolic syndrome.
Sagimet Biosciences
Headquarters
United States of America